Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PML::RARA status confers therapeutic sensitivity to Arsenic trioxide in patients with APL with PML-RARA.
This statement is based on a regulatory approval from the Health Service Executive:
Treatement of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count <= 10x10^9/L)